Drug intelligence / Profile preview

ET-201

Development stage: Unknown
Lead developer: Eton Pharmaceuticals
Administration: Injectable

Overview

ET-201 is an injectable pharmaceutical product that has already received approval and is currently marketed in Europe. Eton Pharmaceuticals has acquired the US rights for this late-stage product from its European owner, with the intention of filing for US FDA approval and subsequently commercializing it in the United States. The drug is expected to leverage Eton's expertise with the 505(b)(2) regulatory pathway for its US approval process.

Beyond the preview

Go deeper on ET-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ET-201.

Explore the full profile